Remibrutinib (Rhapsido) is an oral drug that blocks Bruton's tyrosine kinase (BTK) and reduces the release of histamine and inflammatory mediators in the body[1]. In a phase II study, remibrutinib was tested in adults with a proven allergic reaction to peanut and showed promising results in increasing tolerance to peanut[1]. The benefits of the treatment were already evident within the first week of treatment[1]. After four weeks of treatment, further improvements in symptoms were observed[1]. Remibrutinib has already been approved by the US Food and Drug Administration (FDA) for the treatment of chronic spontaneous urticaria in adults who do not respond adequately to antihistamines[2]. Novartis plans to initiate a phase III program to test remibrutinib in food allergic reactions in the second half of 2026[1]. The most common side effects reported with remibrutinib were nasal congestion, sore throat, runny nose, bleeding, headache, nausea, and abdominal pain[4].